Theraclion Lists on Alternext in Paris

Regulatory News:

EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs¹, today announced the listing of Theraclion (Paris:ALTHE), an echotherapy specialist using high-intensity focused ultrasound (HIFU) for non-invasive treatment of tumours, on Alternext in Paris.

Founded in 2004, Theraclion is a French company that offers a totally non-invasive treatment for benign breast and thyroid tumours. Following ten years of research and development, it developed EchoPulse®, an innovative ultrasound solution harnessing echotherapy for scar-less ablation of breast and thyroid tumours. Solidly protected by 20 international patent families, EchoPulse® has already received the CE mark and now offers an effective alternative to surgery and mini-invasive techniques.

Theraclion (ticker symbol: ALTHE) was listed through the admission to trading of the 2,854,124 ordinary shares making up the company’s equity, of 155,063 new shares created by the conversion of OCA-13 bonds and 1,000,000 new shares issued under a Global Offering².

The admission and issue price of Theraclion shares was set at €14.50 per share. Market capitalisation was around €54.5 million on the day of listing. Altogether the offering raised nearly €10.9 million.

"We are delighted to accompany Theraclion in its listing on Alternext,” said Eric Forest, Chairman and CEO of EnterNext. "This new stage in the company’s development will mean deploying its innovative technology-based solutions on international markets, and will raise Theraclion’s profile with investors,” he noted.

Theraclion CEO Stefano Vagliani added "Our successful listing gives Theraclion the resources we need to become a leading player in a world market estimated at €6 billion³. We are now in a position to step up the development of our distribution network, enhance our R&D efforts and pursue the clinical trials necessary to break into the North American and Chinese markets. Our market listing will also give us greater visibility and facilitate discussions now in progress. I would like to thank all of our employees and partners, in particular Truffle Capital and our new shareholders, for their trust.”

About Theraclion
Based in Paris, Theraclion is an echotherapy specialist and leader in non-invasive treatment of benign tumours with high-intensity focused ultrasound (HIFU) guided by real-time echography. The company has developed a medical device (Echopulse®) that combines advanced ultrasound imaging and HIFU therapy. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. A full 70% of its 19-strong team are dedicated to R&D and clinical trials. Theraclion's main investor since 2005 has been Truffle Capital, a leading European venture capital firm represented on its board of directors by Dr. Philippe Pouletty, and it also receives research funding from Bpifrance (formerly OSEO, the French state innovation agency).
For more information visit www.theraclion.com

About EnterNext
Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level. Euronext is a wholly owned subsidiary of IntercontinentalExchange Group (ICE).

About Euronext
Euronext is the primary exchange in the Euro zone with over 1,300 issuers worth €2.6 trillion in market capitalization, an unmatched blue chip franchise consisting of 20+ issuers in the EURO STOXX 50® benchmark, and a strong diverse domestic and international client base.
Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise of running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs’ access to capital markets.
Euronext is a wholly owned subsidiary of IntercontinentalExchange Group (ICE).

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 - Statements in this press release regarding ICE’s business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 14, 2014.

¹ Small and medium-sized enterprises
² The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.
³ Source : Theraclion